Prognostic value of circulating microRNA-21 for breast cancer: a systematic review and meta-analysis

Wang, Jinling; Sun, Shenghong; Zhang, Jie; Wang, Guinian

doi:10.1080/21691401.2016.1216856

Cited by 40 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We investigated the potential role of circulating miR-21 as a minimally-invasive marker for diagnostic and treatment monitoring marker in breast cancer. Jinling et al, (2017) and have performed meta-analysis of miR-21 expression as prognostic marker involving more than 1,400 breast cancer patients and both studies have shown that upregulation of miR-21 is correlated with shorter overall survival. Two studies (Müller et al, 2014; measured circulating miR-21 expression in a total of 453 breast cancer patients and showed that the upregulation was significantly associated with shorter overall survival.…”

Section: Discussionmentioning

confidence: 99%

Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and Clinical Outcome in Breast Cancer

Anwar

Sari

Kartika

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Aberrant patterns of microRNA expression have been highlighted as a potential clinical biomarker in breast cancer as the most frequent cancer among women that contributes nearly a quarter of total cancer incidence in 2018. Upregulation of microRNA-21 (miR-21) is associated with adverse clinical outcomes in breast cancer. However, the use of circulating free miR-21 as a non-invasive biomarker for diagnosis and therapeutic monitoring in breast cancer is not well established. We quantified the levels of circulating miR-21 expression and analyzed their correlation with clinicopathological variables and progression-free survival. Materials and Methods: This initial study included a cohort of 102 breast cancer patients of different subtypes and clinicat stages. We also included 15 unrelated healthy women. Venous blood from patients was collected at diagnosis and after treatment of surgery and chemotherapy. MiR-21 expression was quantified from total RNA fraction isolated from patient's plasma. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to analyzed miR-21 expression. Results: Expression of circulating miR-21 was significantly elevated in breast cancer patients compared to healthy women (median miR-21 expression levels were 7.67±2.2 and 1.28±0.16, respectively; p<0.0001). Significant reduction of miR-21 expression was observed in breast cancer patients after completion of surgery and chemotherapy (median miR-21 expression levels were 7.67±2.2 at diagnosis and 2.16±1.28 after treatment, respectively; p<0.0001). MiR-21 expression was higher in breast cancer patients younger than 40-year-old but was not significantly different according to different histopathological grades and clinical stages at diagnosis. Patients with upregulation of circulating miR-21 were associated with poor progression-free survival (median survival 72 vs 86 weeks, respectively; log-rank (Mantel-Cox) test, p=0.049). Conclusion: MiR-21 expression was upregulated in breast cancer patients and might serve as a therapeutic monitoring marker.

show abstract

Section: Discussionmentioning

confidence: 99%

Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and Clinical Outcome in Breast Cancer

Anwar

Sari

Kartika

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…MiR-21, located on the chromosome of 17q23.2, has been found to be dysregulated in several cancers including lung cancer [ 11 , 12 ], breast cancer [ 13 , 14 ] and pancreatic cancer [ 15 , 16 ]. The high levels of miR-21 expression in cancers have been reported to be correlated with tumor proliferation, invasion and metastasis [ 17 – 20 ].…”

Section: Introductionmentioning

confidence: 99%

Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis

Guo

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Serum miRNAs have gained great popularity to act as circulating biomarkers of several cancers. In this study, we aimed to evaluate the diagnostic efficiency of serum miR-21 as novel biomarkers for patients with hepatocellular carcinoma (HCC) and other controls. A total of 533 individuals were recruited and conducted in a two-step analysis. The pilot group included 40 HCC patients and 40 healthy donors. The expression levels of miR-21 were significantly higher in primary HCC tissues than in adjacent noncancerous tissues (P<0.0001). HCC patients exhibited significantly higher serum levels of miR-21 than HD (P<0.0001). In the verification group, the mean serum levels of miR-21 in 175 patients with HCC were significantly higher than in 64 with CHB, 78 with LC and 136 HD (all P<0.0001). ROC curves demonstrated that the AUC of miR-21 was 0.849, sensitivity 82.1% and specificity 83.9%. Furthermore, serum miR-21 maintained its diagnostic efficiency in AFP-negative HCC subgroups with AUC 0.831, sensitivity 81.2% and specificity 83.2%. The serum levels of miR-21 could distinguish HCC from CHB and LC (AUC 0.789, sensitivity 76.9%, specificity 85.7% and AUC 0.814, sensitivity 80.8%, specificity 72.9%, respectively). In addition, the serum levels of miR-21 were significantly associated with clinical stage (P=0.006) and distant metastasis (P=0.000). Thus, our findings suggest that miR-21 together with AFP may help enhance the diagnosis of HCC, especially of AFP-negative HCC, and could distinguish HCC from CHB and LC.

show abstract

“…Our results, together with the findings of others, suggest that circulating miR-21 levels, as a novel minimally invasive biomarker, can predict poor prognosis in patients with breast cancer, and its clinical application thus warrants further investigation. [26][27][28][29][30][31][32][33][34][35] Knudsen et al 36 asserted that, in the early stages of the normal-adenoma-adenocarcinoma sequence, the expression levels of miR-17, miR-21, and miR-145 are altered. In our study, when colon cancer cells were compared with control samples, miR-21 expression was found to be upregulated 2.68-fold.…”

Section: Discussionmentioning

confidence: 99%

<p>Associations Between miRNAs and Two Different Cancers: Breast and Colon</p>

Kundaktepe

Sözer

Papila

et al. 2020

CMAR

View full text Add to dashboard Cite

Objective: Screening approaches using microRNAs (miRNAs) have been gaining increased attention owing to their potential applications in the diagnosis, prognosis, and monitoring of cancer, because aberrant miRNA expression plays a role in the development and advancement of malignancies. The objectives of this study were to characterize mir21, miR31, mir143, mir145, and control RNU43, which are differentially expressed in peripheral blood mononuclear cells (PBMCs) of breast and colorectal cancer patients, compared to that in controls and to establish whether this is specific to breast and colon cancer for use as tumor markers. Methods: Thirty newly diagnosed patients with breast cancer and 30 patients with colorectal cancer were enrolled together with 30 healthy controls. PBMCs were isolated from venous blood samples of individuals. Next, miRNA expression analysis was performed by a twostep method of reverse transcription and qPCR. Results: The expression levels of miR-143 and miR-31 were significantly decreased, whereas the expression levels of miR-145 and miR-21 were significantly increased in breast cancer patients compared to those in healthy subjects. Moreover, the expression levels of miR-143, miR-145, and miR-21 were significantly increased and, in contrast, the changes in the expression levels of miR-31 were not statistically significant in colon cancer compared to those in healthy subjects. miR-21 exhibited the highest increase in both breast and colon cancers. There was a weak positive correlation between miR-145 and CA-15.3 in patients with breast cancer (r = 0.451; p = 0.012). miR-143 was positively correlated with the TNM stage in colon cancer patients (r = 0.568; p = 0.001). Conclusion: A biomarker panel composed of miR-21, miR-31, miR-143, and miR-145 in PBMC may provide a new diagnostic approach for the early detection of breast and colon cancer. As miR-21 expression was found to be the highest among all the miRNAs evaluated, it may represent a new tumor biomarker and a candidate therapeutic drug or gene target in colon and breast cancer.

show abstract

Prognostic value of circulating microRNA-21 for breast cancer: a systematic review and meta-analysis

Abstract: Our findings suggest that the circulating miR-21 expression level can predict poor prognosis in patients with breast cancer.

Cited by 40 publications

References 30 publications

Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and Clinical Outcome in Breast Cancer

Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and Clinical Outcome in Breast Cancer

Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis

<p>Associations Between miRNAs and Two Different Cancers: Breast and Colon</p>

Contact Info

Product

Resources

About